Research Library
Curated Studies & Clinical Data
A growing library of peer-reviewed studies, clinical trial data, and systematic reviews organized by compound. Every citation is linked to its primary source.
Semaglutide-Induced Nonarteritic Anterior Ischemic Optic Neuropathy: A Systematic Review and Meta-Analysis
Khani E, Asham H, Rezabakhsh A, et al.
Journal of clinical pharmacology;66(8):e70248
Glucagon-Like Peptide-1 Receptor Agonists for Obstructive Sleep Apnea With and Without Continuous Positive Airway Pressure
Loblundo C, Gao SY, Nguyen SA, et al.
Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2026
Prospective changes in sleep quality and depressive symptom burden following initiation of GLP-1-based therapies in patients with obesity: a real-world study
Kır Y, Haymana C, Toros B, et al.
Journal of endocrinological investigation, 2026
Hunger pain and its reduction; qualitative insight from people with schizophrenia on semaglutide
Rasmussen BS, Simonÿ C, Poulsen ML, et al.
International journal of qualitative studies on health and well-being, 2026;21(1):2717809
Effect of Semaglutide on the Inflammatory Biomarker High-Sensitivity CRP in Patients With Established Cardiovascular Disease and Overweight or Obesity in SELECT: A Prespecified Secondary Analysis
Plutzky J, Bogdański P, Colhoun HM, et al.
Circulation, 2026
Response to “Semaglutide in Diabetic Periodontitis-Induced Osteoblast Ferroptosis: Pharmacological and Methodological Insights” [Response to Letter]
Zhang Z, Niu D, Qiu W, et al.
Drug design, development and therapy, 2026;20:642305
Therapeutic Mechanisms of Resmetirom and Semaglutide in MASLD/MASH: A Review of Inflammatory and Fibrotic Metabolites
Toshikuni N
Metabolites, 2026;16(8)
Tirzepatide for obesity without diabetes: mechanistic insights, clinical evidence, and future directions
He WT, Song YD, Wang XY, et al.
Frontiers in pharmacology, 2026;17:1889594
Beyond Small Molecules: Applying Fragment Molecular Orbital Sygnature Platform (FMO-SP) to Emerging Modalities
Heifetz A, Pillai GG, Taimoory M, et al.
Methods in molecular biology (Clifton, N.J.);3061:91-114
Practical considerations for the use of incretin mimetics in patients with neuroendocrine neoplasms: An expert consensus statement
Grewal US, Ear PH, Sonbol MB, et al.
Cancer;132(16):e70586
Sex-based differences in clinical outcomes among patients with obesity and heart failure with preserved ejection fraction treated with tirzepatide
Mortada I, Lee AW, Buckingham D, et al.
Therapeutic advances in cardiovascular disease, 2026;20:17539447261478928
Efficacy of Luseogliflozin Added to Semaglutide in Patients With Metabolic Dysfunction-Associated Steatohepatitis and Type 2 Diabetes Mellitus: A Randomised, Open-Label Trial
Miyake T, Yoshida O, Furukawa S, et al.
Diabetes, obesity & metabolism, 2026
Recombinant human Thymosin β4 ameliorates experimental colitis and intestinal fibrosis through suppression of mineralocorticoid receptor signaling
Zhao TR, Hu EB, Wang MW, et al.
Molecular biomedicine, 2026;7(1)
Influence of GLP-1 Receptor Agonists on Surgical and Nonsurgical Treatment of Ankle Osteoarthritis
Le Y, Thai S, Siragusa J, et al.
Foot & ankle specialist, 2026;:19386400261471652
Letter: Non-Invasive Tests After Semaglutide in MASH as Disease-Activity Readouts Rather Than Response Biomarkers. Authors’ Reply
Nitze LM, Anstee QM
Alimentary pharmacology & therapeutics, 2026
Review Article: Fibrosis Reversal in Metabolic Dysfunction-Associated Steatohepatitis-The Promise of Emerging Therapeutics
Ayoub M, Tsutsumi T, Rinella ME
Alimentary pharmacology & therapeutics, 2026
Maximizing weight loss with cagrisema: a systematic review and GRADE-assessed meta-analysis of randomized controlled trials
Khan BW, Agha SA, Qamar I, et al.
Naunyn-Schmiedeberg's archives of pharmacology, 2026
Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes
Ruotolo G, Harris C, Lin Y, et al.
Diabetes, obesity & metabolism, 2026
Gastric content and aspiration risk after semaglutide cessation
Chang Y
Anaesthesia, 2026
Efficacy and Safety of Semaglutide in Patients with Polycystic Ovary Syndrome: A Scoping Review
La Vignera S, Condorelli RA
Biomedicines, 2026;14(8)